Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

NCT00566722 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
152
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Abbott